Advanced mosaic influenza vaccine platform to protect people faster and with fewer doses
Official title: Advanced testing of a hexavalent adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment
Funded at Pop Biotechnologies, INC · NIH-11330423 · Data updated 2026-11-12
A new vaccine approach uses a nanoparticle platform to deliver multiple flu antigens together, aiming to provide strong protection with smaller doses and quicker deployment.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pop Biotechnologies, INC NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $948,983 |
| NIH project number | 5R44AI181479-03 |
| Project ID | NIH-11330423 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include individuals at risk for influenza and those who would benefit from rapid, broad-coverage vaccines once the platform advances to human testing.
✕Less likely to help
Patients with conditions that preclude vaccination or have non-flu related immune issues may not benefit from this specific platform.
What this research studies
This project develops and tests a novel influenza vaccine platform that combines HA and NA antigens on SNAP liposomes to create a mosaic nanoparticle vaccine. It uses a cobalt-porphyrin–containing lipid bilayer plus a TLR4-based adjuvant and QS-21 to boost immune responses. The work is conducted in preclinical models to examine dose-sparing, broad protection against multiple flu strains, and rapid manufacturing considerations. If successful, the platform could simplify and speed up responses to seasonal flu and future outbreaks in people. The effort is a Direct to Phase 2 SBIR, moving promising vaccine constructs toward clinical testing.
Why it matters
Potential benefit: If successful, patients could receive effective flu protection with fewer doses and faster deployment during outbreaks.
How similar studies have gone: Preclinical data show protection in mice against multiple flu strains with the mosaic nanoparticle approach, indicating promise for translation to humans.
Where this research is happening
-
Pop Biotechnologies, INC
Buffalo, United States Active
Researchers
- Principal investigator: Kutscher, Hilliard — Pop Biotechnologies, INC
- Study coordinator: Kutscher, Hilliard
Related research
Other NIH-funded projects on the same topics.
-
Creating vaccines for influenza and other infectious diseases
This study is all about creating new vaccines to help protect people from the flu and other infections, so patients can look forward to better options for staying healthy.
-
Creating vaccines for human trials against influenza and other infectious diseases
This study is working on creating new vaccines to help protect people from flu and other infectious diseases, including those that could be used in harmful situations, so that everyone can have safer and more effective options to stay healthy.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Surveillance and preparedness for flu and other respiratory pathogens in Kenya
A US-based research grant aims to improve how Kenya detects and prepares for influenza and other respiratory diseases to protect people there and global health.
-
Enhanced Seasonal Influenza Vaccine Targeting Shared and Variable Viral Antigens
A new DNA-based influenza vaccine approach aims to provide both precise protection against circulating strains and broader defense against unexpected strains.
-
How the immune system responds to flu shots and flu infection
This project looks at how adults' immune systems react after flu shots or when they catch the flu to find why some people get better protection than others.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.